StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Ocular Therapeutix's operating income for the twelve months ending Jun 30, 2026 was -$313.91M. For fiscal 2025 it was -$270.02M. The highest annual figure on record is -$12.90M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$270.02M–
FY2024Dec 31, 2024-$171.78M–
FY2023Dec 31, 2023-$82.38M–
FY2022Dec 31, 2022-$78.65M–
FY2021Dec 31, 2021-$78.04M–
FY2020Dec 31, 2020-$62.85M–
FY2019Dec 31, 2019-$85.80M–
FY2018Dec 31, 2018-$59.12M–
FY2017Dec 31, 2017-$61.92M–
FY2016Dec 31, 2016-$43.33M–
FY2015Dec 31, 2015-$38.20M–
FY2014Dec 31, 2014-$27.09M–
FY2013Dec 31, 2013-$12.90M–
FY2012Dec 31, 2012-$13.67M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$82.11M–
Q1 FY2026Mar 31, 2026-$93.34M–
Q4 FY2025Dec 31, 2025-$69.76M–
Q3 FY2025Sep 30, 2025-$68.70M–
Q2 FY2025Jun 30, 2025-$67.64M–
Q1 FY2025Mar 31, 2025-$63.92M–
Q4 FY2024Dec 31, 2024-$50.58M–
Q3 FY2024Sep 30, 2024-$46.00M–
Q2 FY2024Jun 30, 2024-$43.59M–
Q1 FY2024Mar 31, 2024-$31.62M–
Q4 FY2023Dec 31, 2023-$20.05M–
Q3 FY2023Sep 30, 2023-$19.21M–
Q2 FY2023Jun 30, 2023-$20.57M–
Q1 FY2023Mar 31, 2023-$22.55M–
Q4 FY2022Dec 31, 2022-$19.36M–
Q3 FY2022Sep 30, 2022-$21.54M–
Q2 FY2022Jun 30, 2022-$19.92M–
Q1 FY2022Mar 31, 2022-$17.83M–
Q4 FY2021Dec 31, 2021-$18.05M–
Q3 FY2021Sep 30, 2021-$19.53M–
Q2 FY2021Jun 30, 2021-$20.23M–
Q1 FY2021Mar 31, 2021-$20.23M–
Q4 FY2020Dec 31, 2020-$14.34M–
Q3 FY2020Sep 30, 2020-$14.01M–
Q2 FY2020Jun 30, 2020-$17.88M–
Q1 FY2020Mar 31, 2020-$16.61M–
Q4 FY2019Dec 31, 2019-$21.40M–
Q3 FY2019Sep 30, 2019-$23.14M–
Q2 FY2019Jun 30, 2019-$21.60M–
Q1 FY2019Mar 31, 2019-$19.66M–
Q4 FY2018Dec 31, 2018-$17.28M–
Q3 FY2018Sep 30, 2018-$14.82M–
Q2 FY2018Jun 30, 2018-$13.56M–
Q1 FY2018Mar 31, 2018-$13.46M–
Q4 FY2017Dec 31, 2017-$12.72M–
Q3 FY2017Sep 30, 2017-$15.20M–
Q2 FY2017Jun 30, 2017-$18.34M–
Q1 FY2017Mar 31, 2017-$15.67M–
Q4 FY2016Dec 31, 2016-$12.47M–
Q3 FY2016Sep 30, 2016-$9.24M–

More Ocular Therapeutix figures

See a number that looks wrong?